Real-World Improvement in Above-Target Estimated A1c with Sequential Use of Professional Flash Continuous Glucose Monitoring for Individuals with Diabetes

Professional flash continuous glucose monitoring using the FreeStyle Libre ProTM system is recently available in the U.S. This is one of the first real-world studies evaluating glucose metrics of sequential monitoring periods using a cross-sectional observational design. Between September 2016 and January 2018, de-identified data from 2,836 users having 2 sequential sensors (at least 5 days each) were divided by the 1st sensor above and below an estimated A1c (eA1c) of 7.5%. Glucose metrics for the two sensors were compared. For those starting above an eA1c of 7.5%, the eA1c reduced from 9.6% to 8.7% (-0.9%, p Disclosure R.M. Bergenstal: Research Support; Self; Johnson & Johnson Services, Inc.. Consultant; Self; Johnson & Johnson Services, Inc.. Research Support; Self; Abbott. Advisory Panel; Self; Abbott. Research Support; Self; Becton, Dickinson and Company. Consultant; Self; Becton, Dickinson and Company. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca, Takeda Pharmaceuticals U.S.A., Inc., Dexcom, Inc.. Stock/Shareholder; Self; Merck & Co., Inc.. Research Support; Self; Eli Lilly and Company, Sanofi. Advisory Panel; Self; Sanofi, Roche Pharma. Research Support; Self; Novo Nordisk Inc.. Advisory Panel; Self; Novo Nordisk Inc.. Research Support; Self; Medtronic. Consultant; Self; Medtronic. Research Support; Self; Hygieia. Advisory Panel; Self; Hygieia, Glooko, Inc.. Research Support; Self; JAEB Center For Health Research, JDRF, National Institute of Diabetes and Digestive and Kidney Diseases. T. Dunn: Employee; Self; Abbott. Y. Xu: Employee; Self; Abbott. S. Jangam: Employee; Self; Abbott. G. Hayter: Employee; Self; Abbott.